{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:49:58Z","timestamp":1790196598650,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-022-01763-7","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T15:03:26Z","timestamp":1661526206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"issue":"3","key":"1763_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","volume":"49","author":"JT Rosenbaum","year":"2019","unstructured":"Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum. 2019;49(3):438\u201345.","journal-title":"Semin Arthritis Rheum"},{"key":"1763_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2147\/OPTH.S40268","volume":"7","author":"R Karim","year":"2013","unstructured":"Karim R, Sykakis E, Lightman S, et al. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol. 2013;7:1109\u201344.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"1763_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40265-020-01314-y","volume":"80","author":"LM Valdes","year":"2020","unstructured":"Valdes LM, Sobrin L. Uveitis therapy: the corticosteroid options. Drugs. 2020;80(8):765\u201373.","journal-title":"Drugs"},{"issue":"5","key":"1763_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/jop.2006.0067","volume":"23","author":"ER James","year":"2007","unstructured":"James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403\u201320.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"1763_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","volume":"18","author":"SE Hancock","year":"2021","unstructured":"Hancock SE, Wan C-R, Fisher NE, et al. Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies. Expert Opin Drug Deliv. 2021;18(6):777\u201388.","journal-title":"Expert Opin Drug Deliv"},{"key":"1763_CR6","unstructured":"Clearside Biomedical. XIPERE\u00ae (triamcinolone acetonide injectable suspension), for suprachoroidal use: US prescribing information. 2021. https:\/\/www.xipere.com\/. Accessed 3 Aug 2022."},{"key":"1763_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/989501","volume":"2014","author":"V Sarao","year":"2014","unstructured":"Sarao V, Veritti D, Boscia F, et al. Intravitreal steroids for the treatment of retinal diseases. Sci World J. 2014;2014: 989501.","journal-title":"Sci World J"},{"issue":"2","key":"1763_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/1523-1747.ep12581645","volume":"73","author":"S Hammarstrom","year":"1979","unstructured":"Hammarstrom S, Lindgren JA, Marcelo C, et al. Arachidonic acid transformations in normal and psoriatic skin. J Invest Dermatol. 1979;73(2):180\u20133.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1763_CR9","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1167\/iovs.13-11747","volume":"54","author":"BC Gilger","year":"2013","unstructured":"Gilger BC, Abarca EM, Salmon JH, et al. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest Ophthalmol Vis Sci. 2013;54(4):2483\u201392.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1763_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2007.06.004","volume":"52","author":"CM Jermak","year":"2007","unstructured":"Jermak CM, Dellacroce JT, Heffez J, et al. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52(5):503\u201322.","journal-title":"Surv Ophthalmol"},{"key":"1763_CR11","doi-asserted-by":"crossref","unstructured":"McAllister IL, Vijayasekaran S, Chen SD, et al. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol. 2009;147(5):838\u201346, 46 e1\u20132.","DOI":"10.1016\/j.ajo.2008.12.006"},{"key":"1763_CR12","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0090","author":"L Muya","year":"2022","unstructured":"Muya L, Kansara V, Cavet ME, et al. Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina. J Ocul Pharmacol Ther. 2022. https:\/\/doi.org\/10.1089\/jop.2021.0090.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"1","key":"1763_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1167\/iovs.16-20679","volume":"58","author":"B Chiang","year":"2017","unstructured":"Chiang B, Wang K, Ethier CR, et al. Clearance kinetics and clearance routes of molecules from the suprachoroidal space after microneedle injection. Invest Ophthalmol Vis Sci. 2017;58(1):545\u201354.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1763_CR14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/bjophthalmol-2020-318019","volume":"106","author":"CR Henry","year":"2022","unstructured":"Henry CR, Shah M, Barakat MR, et al. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). Br J Ophthalmol. 2022;106(6):802\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1763_CR15","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","volume":"127","author":"S Yeh","year":"2020","unstructured":"Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948\u201355.","journal-title":"Ophthalmology"},{"key":"1763_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317560","author":"RN Khurana","year":"2021","unstructured":"Khurana RN, Merrill P, Yeh S, et al. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol. 2021. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317560.","journal-title":"Br J Ophthalmol."},{"issue":"6","key":"1763_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/tvst.5.6.14","volume":"5","author":"DA Goldstein","year":"2016","unstructured":"Goldstein DA, Do D, Noronha G, et al. Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Transl Vis Sci Technol. 2016;5(6):14.","journal-title":"Transl Vis Sci Technol."},{"issue":"10","key":"1763_CR18","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1097\/IAE.0000000000002279","volume":"39","author":"S Yeh","year":"2019","unstructured":"Yeh S, Kurup SK, Wang RC, et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). Retina. 2019;39(10):1880\u20138.","journal-title":"Retina"},{"issue":"1","key":"1763_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ceo.14024","volume":"50","author":"MA Singer","year":"2021","unstructured":"Singer MA, Merrill P, Yeh S, et al. Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: a post hoc analysis of PEACHTREE. Clin Exp Ophthalmol. 2021;50(1):23\u201330.","journal-title":"Clin Exp Ophthalmol"},{"key":"1763_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1954199","author":"PT Merrill","year":"2021","unstructured":"Merrill PT, Henry CR, Nguyen QD, et al. Suprachoroidal CLS-TA with and without systemic corticosteroid and\/or steroid-sparing therapy: a post-hoc analysis of the phase 3 PEACHTREE clinical trial. Ocul Immunol Inflamm. 2021. https:\/\/doi.org\/10.1080\/09273948.2021.1954199.","journal-title":"Ocul Immunol Inflamm."},{"key":"1763_CR21","unstructured":"Nguyen QD, Kapik B, Ciulla TA. Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: outcomes by anatomic subtypes in PEACHTREE [abstract no. A0435]. In: ARVO annual meeting. 2022."},{"key":"1763_CR22","unstructured":"Singer MA, Kapik B, Ciulla TA. Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: effect of disease characteristics on clinical outcomes [abstract no. A0433]. In: ARVO annual meeting. 2022."},{"issue":"18","key":"1763_CR23","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.3390\/jcm10184133","volume":"10","author":"SJ Teper","year":"2021","unstructured":"Teper SJ. Update on the management of uveitic macular edema. J Clin Med. 2021;10(18):4133.","journal-title":"J Clin Med"},{"key":"1763_CR24","unstructured":"Alimera Sciences. ILUVIEN\u00ae (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection: US prescribing information. 2016. https:\/\/iluvien.com\/. Accessed 3 Aug 2022."},{"key":"1763_CR25","unstructured":"EyePoint Pharmaceuticals. YUTIQ\u00ae (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection: US prescribing information. 2022. https:\/\/yutiq.com\/. Accessed 3 Aug 2022."},{"key":"1763_CR26","unstructured":"Bausch+Lomb. RETISERT\u00ae (fluocinolone acetonide intravitreal implant) 0.59 mg, for intravitreal use: US prescribing information. 2021. https:\/\/www.bauschretinarx.com\/. Accessed 3 Aug 2022."},{"key":"1763_CR27","doi-asserted-by":"crossref","unstructured":"AbbVie. OZURDEX\u00ae (dexamethasone intravitreal implant), for intravitreal injection: US prescribing information. 2020. https:\/\/www.ozurdex.com\/. Accessed 3 Aug 2022.","DOI":"10.51731\/cjht.2023.535"},{"key":"1763_CR28","unstructured":"US FDA. TRIESENCE\u00ae (triamcinolone acetonide injectable suspension) 40 mg\/mL: US prescribing information. 2007. https:\/\/www.fda.gov\/. Accessed 3 Aug 2022."},{"issue":"3","key":"1763_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/archopht.122.3.336","volume":"122","author":"MC Gillies","year":"2004","unstructured":"Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336\u201340.","journal-title":"Arch Ophthalmol"},{"key":"1763_CR30","unstructured":"Clearside Biomedical. Secondary endpoint: summary of changes in central subfield retinal thickness as measured by SD-OCT. Clearside Biomedical, 2018 (Data on file)."}],"updated-by":[{"DOI":"10.1007\/s40265-022-01777-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01763-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01763-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01763-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T02:44:20Z","timestamp":1676515460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01763-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":30,"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01763-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-022-01777-1","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"2 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-022-01777-1","URL":"https:\/\/doi.org\/10.1007\/s40265-022-01777-1","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Simon Fung and Yahiya Syed are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}